Carregant...
Bortezomib for the treatment of mantle cell lymphoma: an update
Bortezomib is a first in class proteasome inhibitor, initially approved by the US Food and Drug Administration for the treatment of plasma cell myeloma. Bortezomib has been approved for the treatment of relapsed and refractory mantle cell lymphoma (MCL) and, more recently, in the upfront setting as...
Guardat en:
| Publicat a: | Ther Adv Hematol |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4959639/ https://ncbi.nlm.nih.gov/pubmed/27493710 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620716648566 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|